TLR Accessory Molecule RP105 (CD180) Is Involved in Post-Interventional Vascular Remodeling and Soluble RP105 Modulates Neointima Formation

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Karper, Jacco C ^a   Ewing, Mark M ^a   de Vries, Margreet R ^a   de Jager, Saskia C A ^b   Peters, Erna A B ^a   de Boer, Hetty C ^a   van Zonneveld, Anton Jan ^a   Kuiper, Johan ^b   Huizinga, Eric G ^c   Brondijk, T Harma C ^c   Jukema, J Wouter ^a   Quax, Paul H A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 BUTYRYL 1,2,3,4 TETRAHYDROQUINOLINE; ADAPTOR PROTEIN; ANTILIPEMIC AGENT; LIPOPOLYSACCHARIDE; PLASMID VECTOR; PROTEIN MD1; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; BLOOD VESSEL PARAMETERS; COMPLEX FORMATION; CONTROLLED STUDY; DRUG MECHANISM; EX VIVO STUDY; EXTRACELLULAR SPACE; FEMORAL ARTERY; HYPERCHOLESTEROLEMIA; IN VIVO GENE TRANSFER; INTERVENTION STUDY; MOUSE; NEOINTIMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE; WILD TYPE;

ANIMALS; ANTIGENS, CD; ANTIGENS, SURFACE; BLOOD VESSELS; CELL PROLIFERATION; CELLS, CULTURED; FEMORAL ARTERY; GENE EXPRESSION; HEK293 CELLS; HUMANS; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; LIPOPOLYSACCHARIDES; MALE; MEMBRANE GLYCOPROTEINS; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOLUBILITY; TOLL-LIKE RECEPTOR 4;

MURINAE; MUS;

EID: 84879772310     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067923     Document Type: Article

References (34)

1. Jukema JW, Ahmed TA, Verschuren JJ, Quax PH, (2012) Restenosis after PCI. Part 2: prevention and therapy. Nat Rev Cardiol 9: 79-90.
2. Jukema JW, Verschuren JJ, Ahmed TA, Quax PH, (2012) Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol 9: 53-62.
3. Monraats PS, Pires NM, Agema WR, Zwinderman AH, Schepers A, et al. (2005) Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 112: 2417-2425.
4. Hollestelle SC, De Vries MR, Van Keulen JK, Schoneveld AH, Vink A, et al. (2004) Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 109: 393-398.
5. Vink A, Schoneveld AH, van der Meer JJ, Van Middelaar BJ, Sluijter JP, et al. (2002) In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 106: 1985-1990.
6. Karper JC, De Vries MR, van den Brand BT, Hoefer IE, Fischer JW, et al. (2011) Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing reduces vein graft disease in hypercholesterolemic APOE*3Leiden mice. Arterioscler Thromb Vasc Biol 31: 1033-1040.
7. Monraats PS, Pires NM, Schepers A, Agema WR, Boesten LS, et al. (2005) Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J 19: 1998-2004.
8. Schepers A, Eefting D, Bonta PI, Grimbergen JM, De Vries MR, et al. (2006) Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol 26: 2063-2069.
9. de Graaf R, Kloppenburg G, Kitslaar PJ, Bruggeman CA, Stassen F, (2006) Human heat shock protein 60 stimulates vascular smooth muscle cell proliferation through Toll-like receptors 2 and 4. Microbes Infect 8: 1859-1865.
10. Kawai T, Akira S, (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384.
11. Kim HM, Park BS, Kim JI, Kim SE, Lee J, et al. (2007) Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130: 906-917.
12. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, et al. (2006) Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 114: I270-I274.
13. Akashi-Takamura S, Miyake K, (2008) TLR accessory molecules. Curr Opin Immunol 20: 420-425.
14. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, et al. (2005) Inhibition of TLR-4/MD-2 signaling by RP105/MD-1. J Endotoxin Res 11: 363-368.
15. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, et al. (2005) Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol 6: 571-578.
16. Divanovic S, Trompette A, Petiniot LK, Allen JL, Flick LM, et al. (2007) Regulation of TLR4 signaling and the host interface with pathogens and danger: the role of RP105. J Leukoc Biol 82: 265-271.
17. Ohto U, Miyake K, Shimizu T (2011) Crystal Structures of Mouse and Human RP105/MD-1 Complexes Reveal Unique Dimer Organization of the Toll-Like Receptor Family. J Mol Biol. S0022-2836(11)01026-6.
18. Yoon SI, Hong M, Wilson IA, (2011) An unusual dimeric structure and assembly for TLR4 regulator RP105-MD-1. Nat Struct Mol Biol 18: 1028-1035.
19. Freudenberg J, Lee AT, Siminovitch KA, Amos CI, Ballard D, et al. (2010) Locus category based analysis of a large genome-wide association study of rheumatoid arthritis. Hum Mol Genet 19: 3863-3872.
20. Tada Y, Koarada S, Morito F, Mitamura M, Inoue H, et al. (2008) Toll-like receptor homolog RP105 modulates the antigen-presenting cell function and regulates the development of collagen-induced arthritis. Arthritis Res Ther 10: R121.
21. Tanne A, Ma B, Boudou F, Tailleux L, Botella H, et al. (2009) A murine DC-SIGN homologue contributes to early host defense against Mycobacterium tuberculosis J Exp Med. 206: 2205-2220.
22. Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, et al. (2010) B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 207: 1579-1587.
23. Arkenbout EK, de Waard V, van Bragt M, van Achterberg TA, Grimbergen JM, et al. (2002) Protective function of transcription factor TR3 orphan receptor in atherogenesis: decreased lesion formation in carotid artery ligation model in TR3 transgenic mice. Circulation 106: 1530-1535.
24. Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M, (1995) RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family. J Immunol 154: 3333-3340.
25. Lardenoye JH, Delsing DJ, De Vries MR, Deckers MM, Princen HM, et al. (2000) Accelerated atherosclerosis by placement of a perivascular cuff and a cholesterol-rich diet in ApoE*3Leiden transgenic mice. Circ Res 87: 248-253.
26. McMahon JM, Signori E, Wells KE, Fazio VM, Wells DJ, (2001) Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase - increased expression with reduced muscle damage. Gene Ther 8: 1264-1270.
27. Hadley JS, Wang JE, Michaels LC, Dempsey CM, Foster SJ, et al. (2007) Alterations in inflammatory capacity and TLR expression on monocytes and neutrophils after cardiopulmonary bypass. Shock 27: 466-473.
28. Nomura F, Akashi S, Sakao Y, Sato S, Kawai T, et al. (2000) Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol 164: 3476-3479.
29. Eefting D, Schepers A, De Vries MR, Pires NM, Grimbergen JM, et al. (2007) The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. Atherosclerosis 193: 335-342.
30. Eefting D, Seghers L, Grimbergen JM, De Vries MR, de Boer HC, et al. (2010) A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. Cardiovasc Res 88: 367-375.
31. Zhang Y, Xu CB, Cardell LO, (2009) Long-term exposure to IL-1beta enhances Toll-IL-1 receptor-mediated inflammatory signaling in murine airway hyperresponsiveness. Eur Cytokine Netw 20: 148-156.
32. Timmers L, Sluijter JP, Van Keulen JK, Hoefer IE, Nederhoff MG, et al. (2008) Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 102: 257-264.
33. Ward MR, Pasterkamp G, Yeung AC, Borst C, (2000) Arterial remodeling. Mechanisms and clinical implications. Circulation 102: 1186-1191.
34. Miyake K, Shimazu R, Kondo J, Niki T, Akashi S, et al. (1998) Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression. J Immunol 161: 1348-1353.